MedTrace Logo

A Study of Bumetanide for the Treatment of Autism Spectrum Disorders

NCT03156153 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-03-01

No results posted yet for this study

Summary

The investigators are going to carry out a randomized double-blind placebo-controlled trial to study the efficiency and mechanism of bumetanide on the treatment of children with Autism Spectrum Disorder.

Conditions

Interventions

DRUG

Bumetanide

bumetanide tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm

DRUG

Placebo

placebo tablets, oral intake, 0.5mg, twice daily, respectively at 8 am and 4 pm

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Fei Li, doctor · Xinhua hospital Affilated to Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-24
Primary Completion
2019-07-08
Completion
2019-07-10

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03156153 on ClinicalTrials.gov